Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib (Q39601152)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 July 2016

edit

Language	Label	Description	Also known as
English	Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib	scientific article published on 15 July 2016

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

title

Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

main subject

biomarker

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author

Arnaud Méjean

series ordinal

15

object named as

Arnaud Méjean

0 references

Jessica Zucman-Rossi

series ordinal

17

object named as

Jessica Zucman-Rossi

0 references

Benoit Beuselinck

object named as

Benoit Beuselinck

series ordinal

1

0 references

Steven Joniau

object named as

Steven Joniau

series ordinal

8

0 references

Jean-Jacques Patard

series ordinal

13

object named as

Jean-Jacques Patard

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Diether Lambrechts

series ordinal

16

object named as

Diether Lambrechts

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Patrick Schöffski

series ordinal

3

object named as

Patrick Schöffski

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Tania Roskams

series ordinal

12

object named as

Tania Roskams

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

author name string

Johnny Jean-Baptiste

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Gabrielle Couchy

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Clément Meiller

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Frederic Rolland

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Yves Allory

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Virginie Verkarre

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Reza Elaidi

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Evelyne Lerut

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Stephane Oudard

series ordinal

14

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

Arnaud Méjean

series ordinal

15

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

publication date

15 July 2016

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

published in

BJU International

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

volume

118

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

page(s)

890-901

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

cites work

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Resistance to targeted therapy in renal-cell carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Markers of response for the antiangiogenic agent bevacizumab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FBJU.13585

retrieved

21 January 2018

Identifiers

DOI

10.1111/BJU.13585

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

PubMed publication ID

27417418

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27417418

retrieved

13 September 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39601152&oldid=1844176164"